- CA$4.39bn
- CA$4.07bn
- $426.97m
- 94
- 11
- 81
- 64
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 192 | 224 | 251 | 367 | 427 |
Cost of Revenue | |||||
Gross Profit | 138 | 154 | 156 | 236 | 259 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 159 | 203 | 249 | 339 | 413 |
Operating Profit | 32.5 | 20.8 | 1.92 | 27.9 | 14.1 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 35.3 | 21.5 | 1.1 | 31.5 | 19.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | 23.3 | 13.7 | -1.17 | 20.1 | 10.1 |
Net Income Before Extraordinary Items | |||||
Net Income | 23.3 | 13.7 | -1.17 | 20.1 | 10.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 23.3 | 13.7 | -1.17 | 20.1 | 10.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.865 | 0.488 | -0.231 | 0.702 | 0.345 |